spacer
home > > spring 2002 > editor's letter
PUBLICATIONS


Editor's Letter

In 1988 I edited the very first edition of the Technomark Register. At that time we decided to generate two volumes - one for the UK and Ireland and the other for what we chose to call internally 'the rest of Europe'. We set ourselves the objective of including a minimum of 100 CROs as we felt that there was that number of companies in each of the territories. And what a struggle it was. In the end we hit target for the UK, although looking back we did bend the rules a bit by including a few 'one man bands' to make up numbers. A few months later we managed to achieve the same objective for the European volume. I did not calculate the total annual revenue for the companies at that time, but I would be surprised if the total for the whole of Europe was in excess of US$400 million, with a similar figure for North America - effectively at that time 'the rest of the world'. In the 14 years since the first

publication, the market has grown 20-fold to a figure that we estimate to be US$8 billion.
This figure is calculated from the figures reported in the latest editions of the Technomark Register that we have recently published. No longer do we struggle to find 100 companies, no longer do we bend the inclusion rules to make up the numbers. No, we include over 1,500 companies in 40 countries in a mammoth series of volumes that weigh in at over 10kg and occupy 30cm on my bookshelf. (For a detailed discussion of the global CRO market see the article by Marianne O'Neill and myself). It is of constant wonder to me that a market of this sort of scale and scope is as little known and researched as the CRO market. EPC is one of a handful of publications that concentrate exclusively on the CRO scene while books and market research reports are very few and far between. That a market of vital importance to the pharmaceutical industry receives so little attention remains a mystery to me - thank goodness for EPC!


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Graham Hughes
spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stevanato Group signs an agreement with Nelson Labs to provide best-in-class Extractables and Leachables testing services at its US Technology Excellence Center

Piombino Dese, Padua Italy and Salt Lake City, USA September 2, 2020: Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated services for combination products, and Nelson Laboratories, LLC, a global provider of lab testing and expert advisory services signed today a partnership agreement that will provide Extractables and Leachables testing at SG US Technology Excellence Center in Boston, MA.
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

 
Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement